Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
One approach to identifying cancer-specific vulnerabilities and therapeutic targets is to profile genetic dependencies in cancer cell lines. Here, we describe data from a series of siRNA screens that identify the kinase genetic dependencies in 117 cancer cell lines from ten cancer types. By integrating the siRNA screen data with molecular profiling data, including exome sequencing data, we show how vulnerabilities/genetic dependencies that are associated with mutations in specific cancer driver genes can be identified. By integrating additional data sets into this analysis, including protein-protein interaction data, we also demonstrate that the genetic dependencies associated with many cancer driver genes form dense connections on functional interaction networks. We demonstrate the utility of this resource by using it to predict the drug sensitivity of genetically or histologically defined subsets of tumor cell lines, including an increased sensitivity of osteosarcoma cell lines to FGFR inhibitors and SMAD4 mutant tumor cells to mitotic inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950 · cited 3×
“A number of groups have used high-throughput screening approaches such as RNAi or small molecule sensitivity screens to systematically identify genetic dependencies in tumor cell lines (Barretina et al., 2012; Brough et al., 2011; Cowley et al., 2014; Garnett et al., 2012; Koh et al., 2012).”
BackgroundMethodExploring Network Structure, Dynamics, and Function Using NetworkX
Hagberg, A. A., Schult, D. A., & Swart, P. J. (2008) · Proceedings of the Python in Science Conference · doi:10.25080/tcwv9851 · Cited by 7,477 · cited 1×
“The shortest_path function in NetworkX (Hagberg et al., 2008) was also used.”
MethodBang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61121-x · Cited by 7,302
STRING v9.1: protein-protein interaction networks, with increased coverage and integration
Franceschini, A., Szklarczyk, D., Frankild, S., Kuhn, M., Simonovic, M., Roth, A., Lin, J., Minguez, P., Bork, P., von Mering, C., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1094 · Cited by 4,398
A census of human cancer genes
Futreal, P. A., Coin, L., Marshall, M., Down, T., Hubbard, T., Wooster, R., Rahman, N., & Stratton, M. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1299 · Cited by 3,184 · cited 2×
“…200 driver genes prohibited correction for multiple hypothesis testing, we focused our subsequent analysis on 21 key cancer driver genes (12 tumor suppressor genes and nine oncogenes; Futreal et al., 2004; Vogelstein et al., 2013) (Figure 3A) mutated in at least seven tumor cell lines in our panel.”
MethodCRISPR-Cas systems for editing, regulating and targeting genomes
Sander, J. D., & Joung, J. K. (2014) · Nature Biotechnology · doi:10.1038/nbt.2842 · Cited by 3,153 · cited 2×
“Alternatively, 2498 Cell Reports 14, 2490–2501, March 15, 2016 ª2016 The Author methods such as CRISPR-Cas9 mediated gene targeting (Sander and Joung, 2014) might be appropriate.”
MethodSystematic identification of genomic markers of drug sensitivity in cancer cells
Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456 · cited 11×
“(C and D) Box plots of area under curve (AUC) estimates for 58 cell lines exposed to the FGFR inhibitor AZD4547 (C) and PD173074 (D) at eight different concentrations.”
BackgroundMethodInfluentialDPC4 , A Candidate Tumor Suppressor Gene at Human Chromosome 18q21.1
Hahn, S. A., Schutte, M., Shamsul Hoque, A. T. M., Moskaluk, C. A., da Costa, L. T., Rozenblum, E., Weinstein, C. L., Fischer, A., Yeo, C. J., Hruban, R. H., et al. (1996) · Science · doi:10.1126/science.271.5247.350 · Cited by 2,337 · cited 1×
“…tumor suppressor SMAD4, a member of the TGF-b pathway that Reports 14, 2490–2501, March 15, 2016 ª2016 The Authors 2495 is frequently mutated or homozygously deleted in colorectal (Thiagalingam et al., 1996), pancreatic (Hahn et al., 1996), and esophageal (Dulak et al., 2013) cancers (Figure 4B).”
BackgroundUnresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051
Cited by
PARP inhibitors: Synthetic lethality in the clinic
Lord, C. J., & Ashworth, A. (2017) · Science · doi:10.1126/science.aam7344 · Cited by 2,880
Self-citationInduced protein degradation: an emerging drug discovery paradigm
Lai, A. C., & Crews, C. M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.211 · Cited by 1,486
Advances and challenges in targeting FGFR signalling in cancer
Babina, I. S., & Turner, N. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.8 · Cited by 799
Synthetic lethal therapies for cancer: what’s next after PARP inhibitors?
Ashworth, A., & Lord, C. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0055-6 · Cited by 420
Self-citationATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A
Williamson, C. T., Miller, R., Pemberton, H. N., Jones, S. E., Campbell, J., Konde, A., Badham, N., Rafiq, R., Brough, R., Gulati, A., et al. (2016) · Nature Communications · doi:10.1038/ncomms13837 · Cited by 382
Self-citationPathway Commons 2019 Update: integration, analysis and exploration of pathway data
Rodchenkov, I., Babur, O., Luna, A., Aksoy, B. A., Wong, J. V., Fong, D., Franz, M., Siper, M. C., Cheung, M., Wrana, M., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz946 · Cited by 311
Gaspar, N., Campbell-Hewson, Q., Huang, J., Okpara, C. E., & Bautista, F. (2021) · Future Oncology · doi:10.2217/fon-2021-0743 · Cited by 9
Metadata
- Authors
- Campbell, J., Ryan, C. J., Brough, R., Bajrami, I., Pemberton, H. N., Chong, I. Y., Costa-Cabral, S., Frankum, J., Gulati, A., Holme, H., Miller, R., Postel-Vinay, S., Rafiq, R., Wei, W., Williamson, C. T., Quigley, D. A., Tym, J., Al-Lazikani, B., Fenton, T., Natrajan, R., Strauss, S. J., Ashworth, A., & Lord, C. J.
- Venue
- Cell Reports
- Publisher
- Elsevier BV
- Published
- 2016-03
- Volume
- 14
- Issue
- 10
- Pages
- 2490-2501
- ISSN
- 2211-1247 (ISSN-L)
- OpenAlex
- W2291307173
- Cited by
- 101
- References
- 20
- FWCI
- 6.67
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.